Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Share Price

Company Profile

Business description
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Contact
777 Old Saw Mill River Road
TarrytownNY10591-6707
USA
T: +1 914 847-7000
E: [email protected]
https://www.regeneron.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
14,176

Recommended

These stocks could benefit from the race to roll out antibody therapy for covid-19, writes Vikram Barhat.

Vikram Barhat | 15 October 2020

We expect most US adults will be vaccinated in the first half of 2021, writes Morningstar healthcare strategist Karen Andersen.

Karen Andersen, CFA | 01 September 2020

Three new vaccines for coronavirus look poised for emergency use authorisation in the US this autumn. What does that mean for investors?

Karen Andersen, CFA | 22 July 2020

Index	Last price	Change	% Change
All Ordinaries	8,450.90	64.30	-0.76%
CAC 40	7,216.83	10.15	-0.14%
DAX 40	19,003.11	30.53	-0.16%
Dow JONES (US)	43,958.19	47.21	0.11%
FTSE 100	8,030.33	4.56	0.06%
HKSE	19,823.45	23.43	-0.12%
NASDAQ	19,230.74	50.66	-0.26%
Nikkei 225	38,721.66	654.43	-1.66%
NZX 50 Index	12,623.25	51.24	-0.40%
S&P 500	5,985.38	1.39	0.02%
S&P/ASX 200	8,193.40	62.20	-0.75%
SSE Composite Index	3,439.28	17.31	0.51%